New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
08:35 EDTEDAPEDAP submits FDA PMA application for Ablatherm-HIFU
EDAP TMS announced the submission of its Pre-Market Approval, or PMA, application to the FDA on January 31 for the company's Ablatherm-HIFU. or High Intensity Focused Ultrasound, for treatment of low risk, localized prostate cancer. EDAP's PMA submission includes data from the ENLIGHT study, a multi-center U.S. Phase II/III clinical trial that completed the two-year follow-up needed to evaluate its primary endpoint in August 2012, as well as data from the company's extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer.
News For EDAP From The Last 14 Days
Check below for free stories on EDAP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
15:12 EDTEDAPEDAP TMS downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
14:09 EDTEDAPEDAP TMS volatility elevated into FDA meeting
EDAP TMS August option implied volatility is at 228, September is at 151, November is at 106; compared to its 26-week average of 109 according to Track Data, suggesting large price movement into an expected FDA--CDRH - gastroenterology and urology devices panel meeting on June 30.
July 18, 2014
14:08 EDTEDAPEDAP TMS volatility elevated into FDA meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use